← Leaderboards
James W Larrick
Panorama Research, Inc.
$19,609,694
Attributed
$24,901,836
Total exposure
73
Grants
36
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,350,304 · 72
CDC$551,532 · 1
By mechanism
R43$14,278,107 · 64
R44$10,623,729 · 9
Top collaborators
- Bo Yu22 shared
- Andrew R Mendelsohn9 shared
- John C. Cambier2 shared
- Taruna Arora1 shared
- Batbileg Bor1 shared
- Andrzej Fertala1 shared
- Katrin Jennifer Svensson1 shared
- Mohammad Nasir Uddin1 shared
Most similar at Panorama Research, Inc.
Same institution · by research overlap
- Andrew R Mendelsohn$3,743,233
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesDrug KineticsAnimalsIn VitroPre-ClinicalToxic EffectBaseAnimal ModelAffinityIn VivoMediatingCellsAffectHuman Monoclonal AntibodiesPreventMouse ModelSignal TransductionMonoclonal AntibodiesEffective TherapyLeadSafetyBindingProductionBinding (Molecular Function)
Grant awards (85)
Novel Therapy for Sarcopenia$354,000
R43 · FY2025 · AG · contact PI
Novel therapy to prevent alveolar bone loss in severe periodontitis$304,019
R43 · FY2024 · DE · contact PI
Silencing autoantibody secretion for SLE therapy$299,773
R43 · FY2024 · AI
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia$299,989
R43 · FY2023 · NS · contact PI
Silencing autoantibody secretion for SLE therapy$299,865
R43 · FY2023 · AI
Therapy for ectopic calcification in pseudoxanthoma elasticum$285,766
R43 · FY2023 · AR
Novel therapy for arthrofibrosis$275,765
R43 · FY2023 · AR · contact PI
Advancing a novel therapy for preeclampsia$385,000
R43 · FY2022 · HD
Improved carnosic acid congener compounds for Alzheimerâs disease$326,205
R43 · FY2022 · AG
Therapeutic antibody for hyperemesis gravidarum$300,847
R43 · FY2022 · HD
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical$275,766
R43 · FY2022 · GH
Pan-COVID Therapeutic$275,766
R43 · FY2022 · GH
Therapeutic antibody for anorexia nervosa$259,606
R43 · FY2022 · MH
Therapeutic antibody for cancer-associated cachexia$252,282
R43 · FY2021 · CA
Novel therapy for myocardial ischemia-reperfusion injury$252,000
R43 · FY2021 · HL
Inhibiting GPR146 in hypercholesterolemia$249,734
R43 · FY2021 · HL
Targeted therapeutic for Netherton syndrome$252,000
R43 · FY2020 · AR
Targeted Therapy for Type 1 diabetes$250,000
R43 · FY2020 · DK
Novel anti-fibrotic therapy for IPF$224,924
R43 · FY2020 · HL
Monoclonal antibody for autoimmune disease$905,412
R44 · FY2019 · AI · contact PI
Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinsonâs Disease$225,000
R43 · FY2019 · NS
Targeting TGF-beta activation in tumors$224,981
R43 · FY2019 · CA
Human glyco-engineered CHO cells$788,585
R44 · FY2018 · GM
Novel NMDA-targeted Therapy for Alzheimer's Disease$710,940
R44 · FY2018 · AG · contact PI
Monoclonal antibody for autoimmune disease$592,822
R44 · FY2018 · AI · contact PI
Novel GPCR-targeted therapy for preeclampsia$224,986
R43 · FY2018 · HD
Novel therapy for atopic dermatitis$224,981
R43 · FY2018 · AI
Targeting innate immunity in Type 1 diabetes$224,981
R43 · FY2018 · DK
Novel NMDA-targeted Therapy for Alzheimer's Disease$788,076
R44 · FY2017 · AG · contact PI
Human glyco-engineered CHO cells$700,809
R44 · FY2017 · GM
Novel monobody therapy for pancreatic cancer$224,981
R43 · FY2017 · CA
Novel targeted therapeutic for advanced metastatic disease$224,981
R43 · FY2017 · CA
Novel therapy for Goodpasture syndrome$224,393
R43 · FY2017 · DK
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$455,800
R44 · FY2016 · AI · contact PI
Hepcidin Antagonist Therapy for Anemia of Chronic Disease$224,981
R43 · FY2016 · HL · contact PI
Novel therapy for erosive bone disease$224,981
R43 · FY2016 · AG · contact PI
Novel Aminoadamantane Nitrates for the Treatment of Neurological Diseases$224,981
R43 · FY2016 · AG · contact PI
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$499,789
R44 · FY2015 · AI · contact PI
Novel therapy for Netherton syndrome$224,981
R43 · FY2015 · AR · contact PI
Monoclonal antibody for autoimmune disease$224,981
R43 · FY2015 · AI · contact PI
Novel NMDA Receptor Antagonists for Beta Cell Rescue$224,620
R43 · FY2015 · DK · contact PI
Monobody therapy for gynecologic cancers$225,000
R43 · FY2014 · CA · contact PI
Point-of-care immunoassay panel for cardiotonic steroids$224,999
R43 · FY2014 · HD · contact PI
Novel Therapy for Tumor-induced Osteomalacia$224,989
R43 · FY2014 · AR · contact PI
Novel NMDA-targeted Therapy for Alzheimer's Disease$224,667
R43 · FY2014 · AG · contact PI
Novel therapy for disorders of iron overload$224,667
R43 · FY2014 · DK · contact PI
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering$224,310
R43 · FY2014 · AI · contact PI
Tau N-terminal Antibody for Neurodegenerative Tauopathies$293,355
R43 · FY2013 · AG · contact PI
Hepcidin Replacement Therapy for Iron Overload Disorders$289,062
R43 · FY2013 · HL · contact PI
Hetero-dimerization-activated Antibodies$295,502
R43 · FY2012 · AI · contact PI
Novel anti-ganglioside therapy$294,070
R43 · FY2012 · CA · contact PI
Novel Therapy for Preeclampsia$226,814
R43 · FY2012 · HD · contact PI
Monobody for Renal Inflammaton$241,123
R43 · FY2011 · AI · contact PI
Myocardial Repair by Targeted Stem Cells$882,950
R44 · FY2009 · HL · contact PI
Novel Therapy for Diabetic Complications Using RAGE-Fc$290,088
R44 · FY2009 · DK · contact PI
Inotropic Antibodies$198,909
R43 · FY2009 · HL · contact PI
Myocardial Repair by Targeted Stem Cells$903,306
R44 · FY2008 · HL · contact PI
Novel Therapy for Diabetic Complications Using RAGE-Fc$323,185
R44 · FY2008 · DK · contact PI
Novel Therapy for the Common Cold$202,022
R44 · FY2008 · AI · contact PI
Kinetic Assembly of Bispecific Antibodies$170,289
R43 · FY2008 · CA · contact PI
Novel Therapy for Chronic Non-healing Wounds$143,100
R43 · FY2008 · GM · contact PI
Novel Immunoadhesin Molecule for Cancer Therapy$329,320
R44 · FY2007 · CA · contact PI
Novel BiSpecific Antibodies$190,350
R43 · FY2007 · CA · contact PI
Rational Psoriasis Therapy$189,720
R43 · FY2007 · AR · contact PI
Novel Immunoadhesin Molecule for Cancer Therapy$394,331
R44 · FY2006 · CA · contact PI
Targeted Enzyme for HCC$158,841
R43 · FY2006 · CA · contact PI
Novel Therapy for Diabetic Complications Using RAGE-Fc$148,400
R43 · FY2006 · DK · contact PI
Novel Therapy for Hepatocellular Carcinoma$133,000
R43 · FY2005 · CA
Myocardial repair by targeted stem cells$105,735
R43 · FY2005 · HL
Pathogen Detection with Immunological Capture and BRC$100,000
R43 · FY2004 · AI
Novel Therapy for the Common Cold$148,200
R44 · FY2003 · AI
Novel Antibody-Based Therapy for Autoimmune Disease$140,000
R43 · FY2003 · AI
A Novel Technology for Molecular Evolution$107,000
R43 · FY2003 · AI
A Novel Hepatokine$100,000
R43 · FY2003 · DK
Novel Antimicrobial Therapy$100,000
R43 · FY2003 · AI
An Endogenous Cardioprotectant$98,007
R43 · FY2003 · HL
Novel Therapy for the Common Cold$894,929
R44 · FY2002 · AI
Human antibody immunotherapy for Alzheimer's Disease$131,241
R43 · FY2002 · AG
Novel Anti-quorum Sensing Agent$100,000
R43 · FY2002 · AI
Novel Therapy for the Common Cold$455,650
R44 · FY2001 · AI
NOVEL THERAPY FOR ALLERGIC DISEASE$100,000
R43 · FY2001 · AI
RAPID HOMOGEONEOUS HEMAGGLUTINATION ASSAY FOR HIV$357,515
R44 · FY2000 · AI
NOVEL THERAPY FOR KAPOSI'S SARCOMA$102,841
R43 · FY2000 · CA
NOVEL RAPID TEST FOR CARIOGENIC BACTERIA$100,000
R43 · FY2000 · DE
NOVEL IMMUNOTHERAPY FOR HIV$100,000
R43 · FY2000 · AI